BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Clinical Outcome
16 results:

  • 1. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
    Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
    J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinicopathological Features and outcomes in Individuals with breast cancer and atm, CHEK2, or PALB2 Mutations.
    Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S
    Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis.
    Zhang S; Qiu D; Xie X; Shen Y
    BMC Cancer; 2020 Apr; 20(1):343. PubMed ID: 32321469
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
    Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
    Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.
    Sagredo EA; Blanco A; Sagredo AI; Pérez P; Sepúlveda-Hermosilla G; Morales F; Müller B; Verdugo R; Marcelain K; Harismendy O; Armisén R
    Biol Res; 2018 Oct; 51(1):36. PubMed ID: 30290838
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and atm phosphorylation.
    Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
    Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Current Advances in Thyroid cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
    Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
    Ho D; Huang J; Chapman JW; Leitzel K; Ali SM; Shepherd L; Parulekar WR; Ellis CE; Crescnzo RJ; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon KA; Carney WP; Lipton A
    Breast Cancer Res Treat; 2017 Aug; 164(3):571-580. PubMed ID: 28484925
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients.
    Wan G; Xiang L; Sun X; Wang X; Li H; Ge W; Cao F
    Oncotarget; 2017 Jan; 8(3):5382-5391. PubMed ID: 28036271
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Low Ki67/high atm protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.
    Feng X; Li H; Kornaga EN; Dean M; Lees-Miller SP; Riabowol K; Magliocco AM; Morris D; Watson PH; Enwere EK; Bebb G; Paterson A
    Oncotarget; 2016 Dec; 7(52):85798-85812. PubMed ID: 27741524
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Low atm protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
    Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
    Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
    Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
    Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
    Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis.
    Sarasin A; Kauffmann A
    Mutat Res; 2008; 659(1-2):49-55. PubMed ID: 18308619
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. breast cancer in female carriers of atm gene alterations: outcome of adjuvant radiotherapy.
    Meyer A; John E; Dörk T; Sohn C; Karstens JH; Bremer M
    Radiother Oncol; 2004 Sep; 72(3):319-23. PubMed ID: 15450731
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.